Schering-Plough R&D increased by 41.1% to $8.54M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 41.1%, from $6.05M to $8.54M.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $5.00M | $5.00M | $5.00M | $5.00M | $6.05M | $8.54M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +21.1% | +41.1% |
| YoY Change | — | — | — | — | +21.1% | +41.1% |